Trials / Completed
CompletedNCT01053715
Quality of Life Study of Helixate NexGen
A European, Prospective, Non-Interventional Study to Assess Health Related Quality of Life and to Identify Key Transitional Life Events in Patients With Moderate or Severe Haemophilia A Using Helixate NexGen
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 78 (actual)
- Sponsor
- CSL Behring · Industry
- Sex
- Male
- Age
- 14 Years – 35 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to describe Health Related Quality of Life (HRQoL) in adolescents and adults with Hemophilia A treated prophylactically or on-demand with Helixate NexGen. The study will also assess the kinds of determinants, including key transitional life events, that might impact HRQoL in this patient population.
Conditions
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2010-01-21
- Last updated
- 2015-03-20
Locations
31 sites across 7 countries: Austria, Belgium, France, Germany, Italy, Spain, Switzerland
Source: ClinicalTrials.gov record NCT01053715. Inclusion in this directory is not an endorsement.